

TBVI Symposium 2026

Maison des Congrès, Les Diablerets

Tuesday, 27 January 2026



Welcome and Opening – TBVI	13:30-13:35
TBVI Awards 2026 – TBVI	13:35-13:45
Vaccine Development Pathway/Roadmap – Elly van Riet & Marit Holleman, TBVI	13:45-14:00

1. Innovating and Diversifying the TB Vaccine Pipeline

a. Mechanisms of Action – (chair: Frank Verreck)

<u>“Trained immunity: from mechanisms to vaccines”</u> – Mihai Netea, Radboud University	14:00-14:30
<u>“Local immunity in the lung”</u> – Steffen Stenger, Institute of Medical Microbiology and Hygiene	14:30-14:50
<u>“Characterising lung mucosal and systemic immune response in humans following inhalation of attenuated Mycobacterium bovis BCG using single cell sequencing”</u> – TBVI Awardee Shuailin Li, University of Oxford	14:50-15:10
<u>“Next-Generation Nucleic Acid-Based Vaccine for Targeting MTB Persisters”</u> – Petros Karakousis, Johns Hopkins University School of Medicine	15:10-15:30
<u>“High-endothelial venules represent a vaccine-inducible backdoor for homing of T cells in Mycobacterium tuberculosis lung lesions”</u> – TBVI Awardee Nafsika Panagiotopoulou, Statens Serum Institut	15:30-15:50
Q&A	15:50-16:10

Group Photo

16:10-16:15

Coffee Break

16:15-16:45

b. Preclinical Mucosal Vaccine Candidates – chair: Camille Locht

<u>“Challenges in mucosal TB vaccine development including the story of Spore-FP1 candidate”</u> – Rajko Reljic, City St George's University of London	16:45-17:15
<u>“A novel Th17-inducing mucosal vaccine for tuberculosis”</u> – Mushtaq Ahmed, University of Chicago	17:15-17:35
<u>“Improving lung immunity with next generation TB subunit vaccines”</u> – Helen McShane, University of Oxford	17:35-17:55
Q&A	17:55-18:15
Wrap-up Summary, Evening Programme & Outlook to Wednesday – TBVI	18:15-18:20
<u>Raising awareness of tuberculosis through gamification: the Tuberculosis Alert board game</u> – Cris Vilaplana and Maria Vidal, IGTP-HUGTIP	18:20-18:30
Reception	19:00-19:30
Dinner	19:30
TB Alert Game (Hotel Lobby Area)	21:00

TBVI Symposium 2026

Maison des Congrès, Les Diablerets

Wednesday, 28 January 2026



Welcome of the Day – TBVI 08:30-08:35

2 Accelerating Clinical Development – chair: Frank Cobelens

“Accelerating clinical development” – Frank Cobelens, Amsterdam UMC/
Amsterdam Institute for Global Health and Development 08:35-08:40

“The TB Vaccine Clinical Pipeline and Lessons Learned from Recent Trials” –
Mark Hatherill, University of Cape Town 08:40-09:00

“Symptom-agnostic endpoints” – Gavin Churchyard, The Aurum Institute 09:00-09:20

Panel Discussion – “Clinical trial design; subclinical, IGRA-/IGRA+ (SAGE report)” –
moderated by Frank Cobelens and Mark Hatherill – Panel Alex Schmidt, Gates
Foundation, Gavin Churchyard, Aurum Institute, Michele Tameris SATVI, University of
Cape Town, Morten Ruhwold, NIVI Development 09:20-09:50

Coffee & Networking Break

09:50-10:20

3 Ensuring Public Health Impact; preparing for roll out during development – chair: Richard White

Introduction – Richard White 10:20-10:25

“Looking ahead during development” – Richard White, LSHTM, Elly van Riet, TBVI 10:25-10:45

“How modelling can support thinking about potentially maximizing public health
impact” – TBVI Awardee Rebecca Clark, LSHTM 10:45-11:05

“Shaping a Global Access roadmap: developers’ perspective” – Eliana Pombo,
Biofabri 11:05-11:25

“WHO perspective – ongoing/planned pre-licensure activities to maximise public
health impact” – Birgitte Giersing, World Health Organization 11:25-11:45

Panel Discussion – moderated by Richard White – Panel Willem Hanekom, AHRI,
Birgitte Giersing, WHO, Kristin Croucher, Gates Foundation, Claudia Crowell,
BioNtech, Alemnew Dagneu, Gates MRI 11:45-12:25

Closure – TBVI 12:25-12:30